$6.70
3.32% yesterday
Nasdaq, Jul 01, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

MiMedx Group, Inc. Share price

$6.70
-0.40 5.63% 1M
-2.07 23.60% 6M
-2.07 23.60% YTD
+0.10 1.52% 1Y
-6.22 48.14% 3Y
+2.71 67.92% 5Y
-0.77 10.31% 10Y
Nasdaq, Closing price Mon, Jul 01 2024
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

Key figures

Market capitalization $988.95m
Enterprise Value $959.91m
PER (TTM) P/E ratio 14.43
EV/FCF (TTM) EV/FCF 28.91
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 2.96
P/B ratio (TTM) P/B ratio 6.35
Sales growth (TTM) Sales growth 19.20%
Turnover (TTM) Turnover $334.51m
EBIT (operating result TTM) EBIT $45.81m
Free cash flow (TTM) Free cash flow $33.20m
Cash position $48.49m
EPS (TTM) EPS $0.46
P/E ratio expected 21.85
P/S ratio expected 2.75
EV/Sales expected 2.67
Short interest 4.74%
Show more

Is MiMedx Group, Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

MiMedx Group, Inc. Share analysis

Unlock scores for free

Analyst opinions

5 Analysts have issued a MiMedx Group, Inc. forecast:

5x Buy
100%

Analyst opinions

5 Analysts have issued a MiMedx Group, Inc. forecast:

Buy
100%

Financial data from MiMedx Group, Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
85 85
18% 18%
100%
- Direct costs 13 13
5% 5%
16%
72 72
21% 21%
84%
- Selling and administrative expenses 55 55
0% 0%
65%
- Research and development costs 2.84 2.84
56% 56%
3%
14 14
754% 754%
17%
- Depreciation and amortization 0.75 0.75
40% 40%
1%
EBIT (operating result) EBIT 13 13
492% 492%
16%
Net profit 9.26 9.26
286% 286%
11%

Figures in millions USD.

Don't miss a thing! We will send you all news about the MiMedx Group, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

MiMedx Group, Inc. Share News

Positive
InvestorPlace
about 8 hours ago
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Neutral
GlobeNewsWire
5 days ago
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.
Neutral
GlobeNewsWire
about 2 months ago
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
More MiMedx Group, Inc. News

Company profile

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.

Head office United States
CEO Joe Capper
Employees 895
Founded 1985
Website www.mimedx.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now